
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT
- About
Tango Therapeutics Inc (TNGX)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: TNGX (3-star) is a STRONG-BUY. BUY since 59 days. Profits (266.14%). Updated daily EoD!
1 Year Target Price $10.86
1 Year Target Price $10.86
6 | Strong Buy |
2 | Buy |
0 | Hold |
0 | Sell |
0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 377.16% | Avg. Invested days 40 | Today’s Advisory Strong Buy |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 769.92M USD | Price to earnings Ratio - | 1Y Target Price 10.86 |
Price to earnings Ratio - | 1Y Target Price 10.86 | ||
Volume (30-day avg) 8 | Beta 1.64 | 52 Weeks Range 1.03 - 12.02 | Updated Date 08/15/2025 |
52 Weeks Range 1.03 - 12.02 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.32 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-08-05 | When - | Estimate -0.35 | Actual -0.35 |
Profitability
Profit Margin - | Operating Margin (TTM) -1287.87% |
Management Effectiveness
Return on Assets (TTM) -31.74% | Return on Equity (TTM) -76.09% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 624143909 | Price to Sales(TTM) 31.69 |
Enterprise Value 624143909 | Price to Sales(TTM) 31.69 | ||
Enterprise Value to Revenue 25.69 | Enterprise Value to EBITDA -0.91 | Shares Outstanding 111260000 | Shares Floating 48379293 |
Shares Outstanding 111260000 | Shares Floating 48379293 | ||
Percent Insiders 12.26 | Percent Institutions 96.54 |
Upturn AI SWOT
Tango Therapeutics Inc
Company Overview
History and Background
Tango Therapeutics, Inc. is a biotechnology company focused on discovering and developing novel cancer therapeutics. Founded in 2017, the company leverages its functional genomics platform to identify and validate novel drug targets in genetically defined cancer patient populations. They went public via IPO in 2021. Their approach is focused on synthetic lethality.
Core Business Areas
- Drug Discovery & Development: Tango's primary focus is on identifying and developing novel drug candidates targeting specific cancer vulnerabilities through synthetic lethality. This includes target validation, drug design, preclinical studies, and clinical trials.
- Functional Genomics Platform: The company utilizes its proprietary functional genomics platform to identify new cancer targets and understand drug resistance mechanisms.
- Partnerships: Tango collaborates with pharmaceutical companies to accelerate drug development and expand its pipeline. Their most prominent partnership is with Gilead Sciences.
Leadership and Structure
Barbara Weber, M.D., is the CEO. The management team consists of experienced professionals in drug discovery, development, and commercialization. The company has a Board of Directors providing strategic oversight.
Top Products and Market Share
Key Offerings
- TNG908: TNG908 is Tango's lead clinical program, a MTA-cooperative PRMT5 inhibitor. It is currently in Phase 1/2 clinical trials for MTAP-deleted cancers. There is no direct market share yet, as it is still in clinical development. Competitors in the PRMT5 inhibitor space include companies like Mirati Therapeutics and Artios Pharma.
- TNGO29: TNGO29 is a preclinical program targeting USP1. It is being developed as a potential treatment for BRCA1/2-mutant cancers and other tumors deficient in DNA damage repair. There is no direct market share yet, as it is still in preclinical development. The competitive landscape includes other companies developing therapies targeting DNA damage repair pathways.
Market Dynamics
Industry Overview
The biotechnology industry is characterized by high risk, high reward, and intense competition. Advances in genomics and personalized medicine are driving the development of targeted therapies, including those based on synthetic lethality. The industry is heavily regulated and requires significant capital investment.
Positioning
Tango Therapeutics is positioned as a leader in the field of synthetic lethality. Its functional genomics platform gives it a competitive advantage in identifying and validating novel drug targets. The Gilead partnership validates their technology and provides financial resources.
Total Addressable Market (TAM)
The total addressable market for cancer therapies is estimated to be in the hundreds of billions of dollars. Tango is positioned to capture a portion of this market by developing therapies for genetically defined cancer patient populations.
Upturn SWOT Analysis
Strengths
- Proprietary functional genomics platform
- Strong scientific team
- Strategic partnership with Gilead Sciences
- Focus on genetically defined patient populations
- Novel approach to drug discovery (synthetic lethality)
Weaknesses
- Early-stage clinical pipeline (high risk)
- Limited financial resources compared to larger pharmaceutical companies
- Reliance on partnerships for funding
- No approved products yet
Opportunities
- Expansion of pipeline through internal discovery and partnerships
- Advancement of clinical programs to late-stage development
- Potential for breakthrough therapies in underserved patient populations
- Increased adoption of personalized medicine approaches
Threats
- Clinical trial failures
- Competition from other biotechnology and pharmaceutical companies
- Regulatory hurdles
- Patent challenges
- Economic downturn impacting funding
Competitors and Market Share
Key Competitors
- MRTX
- ARTL
- GILD
- ARRY
Competitive Landscape
Tango's advantage lies in its functional genomics platform. Its disadvantage is its smaller size and limited resources compared to established pharmaceutical companies. Gilead offers a strong partnership.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is primarily characterized by preclinical and early clinical development activities. They became a public company in 2021.
Future Projections: Future growth depends on the successful development and commercialization of its pipeline. Analyst estimates vary widely based on clinical trial outcomes.
Recent Initiatives: Recent initiatives include advancing TNG908 through clinical trials, expanding their pipeline of preclinical programs, and exploring new partnerships.
Summary
Tango Therapeutics is an early-stage biotech company with a promising functional genomics platform focused on synthetic lethality. Its Gilead partnership provides significant validation and funding. The success of its lead clinical program, TNG908, and pipeline expansion are key to future growth, but clinical trial risks and competition from larger players remain significant concerns.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Tango Therapeutics' Website
- Tango Therapeutics' SEC Filings
- Industry Reports
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The information is based on publicly available data and analyst estimates, which are subject to change. Investing in biotechnology companies is inherently risky.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Tango Therapeutics Inc
Exchange NASDAQ | Headquaters Boston, MA, United States | ||
IPO Launch date 2020-09-03 | President, CEO & Director Dr. Barbara L. Weber M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 155 | Website https://www.tangotx.com |
Full time employees 155 | Website https://www.tangotx.com |
Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma. It is developing TNG260, a co-repressor of repressor element-1 silencing transcription inhibitor to reverse the immune evasion effect of serine-threonine kinase 11 loss-of-function mutations for treating lung cancer. The company was founded in 2017 and is headquartered in Boston, Massachusetts.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.